) for which clinical data were also available. The 204 samples 2 8 1 were randomly divided into seven batches and digested into peptides in barocyclers. Every We then subjected the resulting peptide samples to the15-min-SWATH method optimized missing value rate. On average, 5,615 peptide precursors from 1,018 proteins were quantified 2 9 0 for each sample. More peptides and proteins were quantified from tumor samples (5,861 2 9 1 peptide precursors from 1,078 proteins on average) than benign samples (3,988 peptide 2 9 2 precursors from 618 proteins on average). Totally 913 proteins were quantified in at least 50% 2 9 3 samples ( Supplementary Table 3 ).
9 4
To allow a comparison of the accelerated short gradient method with a standard SWATH 2 9 5 MS method with respect to the number of proteins recorded and the respective clinically 2 9 6 relevant information content we re-acquired the whole sample set with a 120-min LC gradient 2 9 7 and 48 variable Q1 windows in a TripleTOF 5600+(26). These measurements consumed 467 2 9 8 hr (~20 days) and identified 38,338 peptide precursors from 5,059 SwissProt proteins with 2 9 9 61.86% missing value rate. On average, 10,751 peptide precursors from 1,921 proteins were 3 0 0 quantified for each sample. More peptides and proteins were quantified from tumor samples 3 0 1 (11,439 peptide precursors from 2,054 proteins on average) than benign samples (6,693 3 0 2 peptide precursors from 1192 proteins on average). Totally 1,914 proteins were quantified in 3 0 3 at least 50% samples ( Supplementary Table 3 ). Compare to this 120-min method, the 15-min 3 0 4 method characterized about half of peptide precursors and proteins. Overall, the data shows that the 15-min-SWATH coverage reached 50-80% of that 3 0 7 achieved by a standard method. In all samples, 3,800 proteins were quantified by both 3 0 8 methods. This result was generated at a 6-fold reduced acquisition time (time 125.7 hrs vs, 3 0 9 467 hrs) ( Figure 1b ) suggesting that clinical cohorts of significant size can be measured by the 3 1 0 accelerated method quickly, efficiently.
1 1
Reproducibility and batch effect analysis 3 1 2
We evaluated the reproducibility of the datasets produced by the 15-min gradient and the 120-3 1 3 min gradient SWATH with respect to reproducibility and batch effect. We first assessed the 3 1 4 technical reproducibility by correlation between technical replicates for LC-MS. The 3 1 5 technical reproducibility of the data obtained by the 15-min SWATH method (r = 0.99) is 3 1 6 slightly higher than that from the 120-min SWATH method (r = 0.86) (Figure 2a ). Thus, the 3 1 7 measured biological reproducibility is also slightly higher in the 15-min SWATH method 3 1 8 ( Figure 2a ). If we focused the analysis on the 3,800 proteins quantified by both methods, we 3 1 9 observed a high degree of similarity (r = 0.7681) between the methods (Figure 2b ).
2 0
We next analyzed batch effects apparent in either dataset. Batch effects are an 3 2 1 unavoidable reality resulting from technical variation in multi-day MS analyses and are a 3 2 2 non-trivial complication for big cohort proteomics analysis. Several algorithms have been 3 2 3 developed to bioinformatically minimize the missing value rate, however, these imputation 3 2 4 approaches remain controversial (31). We evaluated the batch effect of the data acquired by 3 2 5 the 15-min SWATH, which is lower than that from the 120-min method ( Figure 2c ). Together, 3 2 6 the 15-min SWATH method improved quantitative reproducibility and reduced batch effect. On the path to clinical or preclinical use protein biomarkers detected by MS based cohort 3 3 0 studies face a number of verification and validation requirements. These include technical 3 3 1 verification of the abundance changes detected in the cohort study and validation in 3 3 2 independent sample cohorts.
3
To further validation the abundance changes detected in the SWATH data we selected a respective intensities using the targeted MS method MRM-HR. The selected proteins were 3 3 7 associated with most strongly cancer dis regulated pathways and included 21 known 3 3 8 diagnosis biomarkers such as ACPP and FASN, and 10 drug targets (Supplementary Table   3 3 9 4A). The proteins were further annotated in IPA ( Supplementary Table 4B ) indicating that the 3 4 0 proteins suggested elevated cell migration, development and growth, and suppressed cell 3 4 1 death and survival (Supplementary Figure 5 ).
4 2
For these measurements the MRM-HR method was optimized using a pooled prostate 3 4 3 sample to determine the best performing peptides from the selected proteins, and best target were selected for targeted detection ( Supplementary Table 2E ). Time scheduling was used to 3 4 7 ensure at least eight data points were obtained across the LC peaks as well as an optimized 3 4 8 accumulation time of 25 ms for each peptide for high-quality quantitative data.
4 9
To confirm the quantitative accuracy of the 15-min SWATH data, we re-analyzed 99 3 5 0 samples in the PCZA cohort using the MRM-HR method. The 99 samples were randomly we found that 76.6% of precursors measured from the peptides were quantified with a CV 3 5 5 below 20%. The median CV was 13.4% (Supplementary Figure 6 ). Next the protein 3 5 6 fold-changes between tumor and normal samples were calculated to investigate the 3 5 7 correlation of 15-min SWATH with MRM-HR ( Figure 3a ).
5 8
We further quantified the expression levels of the 75-protein-panel in an independent 3 5 9 prostate cancer cohort, PCZB, containing 30 BPH and 24 PCa in duplicated biological 3 6 0 replicates using the same 15-min SWATH MRM-HR workflow ( Supplementary Table 5 ). For 3 6 1 the six pooled samples measured across six batches, 75.6% of peptide precursors were 3 6 2 quantified with a CV below 20%. The median CV is 14.9% (Supplementary Figure 6 ).
6 3
To assess the power of the protein panel of differentially abundant proteins to separate 3 6 4 benign and malignant tissues, we assembled a random-forest model for the PCZA MRM-HR 3 6 5 dataset, and found an accuracy of 0.992 in this set ( Supplementary Figure 7 ). Next, we tested We then investigated in detail two proteins-PRDX3 (P30048) and COPA (P53621) which samples are shown in Supplementary Figure 9 , with all of AUC over 0.78. Taken together, we 3 7 7 validated these dysregulated proteins quantification by SWATH showed higher reliability and 3 7 8 performed better prediction ability in different sample cohorts. In this study, we present a 15-min microflow-LC SWATH that supports the consistent accuracy of the short gradient method was comparable to that achieved by targeted 3 9 0 quantification using MRM-HR for shortlisted proteins. This work showed the potential of this 3 9 1 short gradient SWATH proteomics pipeline for accelerated discovery and verification of 3 9 2 protein biomarkers for precision medicine. . 
